Tumour lysis syndrome: an unexpected adverse event associated with ipilimumab

J Eur Acad Dermatol Venereol. 2017 Feb;31(2):e73-e74. doi: 10.1111/jdv.13733. Epub 2016 Jun 3.

Authors

M Masson Regnault¹, J Ofaiche¹, S Boulinguez¹, E Tournier¹, P Rochaix², C Paul¹, L Lamant^{2

3}, N Meyer^{1

3}

Affiliations

¹ Dermatology, Université Paul-Sabatier-Toulouse III and Institut Universitaire du Cancer de Toulouse, Toulouse, France.
² Pathology, Université Paul-Sabatier-Toulouse III and Institut Universitaire du Cancer de Toulouse, Toulouse, France.
³ INSERM UMR 1037-CRCT, Toulouse, France.

PMID: 27256718
DOI: 10.1111/jdv.13733

No abstract available

Publication types

Letter

MeSH terms

Adult
Aged
Antibodies, Monoclonal / adverse effects*
Female
Humans
Ipilimumab
Male
Melanoma / etiology*
Middle Aged
Tumor Lysis Syndrome / etiology*

Substances

Antibodies, Monoclonal
Ipilimumab